Clearmind Medicine Inc (FRA:CWY0) Stock Price, Trades & News

Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.

Financial Strength

8/10

Name	Current	Vs Industry
Cash-To-Debt	159.92
Equity-to-Asset	0.79
Debt-to-Equity	0.01
Debt-to-EBITDA	-0.01
Piotroski F-Score	2/9	0 1 2 3 4 5 6 7 8 9
WACC vs ROIC		WACC ROIC

Growth Rank

	Name	Current	Vs Industry		Vs History
	3-Year EBITDA Growth Rate	3.9
	3-Year EPS without NRI Growth Rate	81
	3-Year FCF Growth Rate	-27

Momentum Rank

1/10

	Name	Current	Vs Industry		Vs History
	9-Day RSI	15.14
	14-Day RSI	17.6
	12-1 Month Momentum %	-93.09

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	4.79
	Quick Ratio	4.79
	Cash Ratio	4.55

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	8.7
	Shareholder Yield %	-283.72

Profitability Rank

1/10

	Name	Current	Vs Industry		Vs History
	ROE %	-162.73
	ROA %	-96.64
	ROIC %	-301.74
	3-Year ROIIC %	16.39
	ROC (Joel Greenblatt) %	-22760.12
	ROCE %	-161.81
	Moat Score	3
	Tariff Resilience Score	8

GF Value Rank

	Name	Current	Vs Industry		Vs History
	PB Ratio	0.16
	Price-to-Tangible-Book	0.16
	EV-to-EBIT	1.34
	EV-to-EBITDA	1.35
	EV-to-FCF	1.74
	Price-to-Net-Current-Asset-Value	0.16
	Price-to-Net-Cash	0.18
	Earnings Yield (Greenblatt) %	74.74
	FCF Yield %	-210.5

Financials (Next Earnings Date:2026-09-11 Est.)

Annual Quarterly TTM

FRA:CWY0's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Clearmind Medicine Inc Executives

Details

GF Value™

FRA:CWY0

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 1 Severe warning sign with CWY0. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)
	EPS (TTM) (€)	-160.552
	Beta	-1.7398
	3-Year Sharpe Ratio	-1.06
	3-Year Sortino Ratio	-1.2
	Volatility %	92.18
	14-Day RSI	17.6
	14-Day ATR (€)	0.000112
	20-Day SMA (€)	22.56
	12-1 Month Momentum %	-93.09
	52-Week Range (€)	22.55 - 391
	Shares Outstanding (Mil)	1.49

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	2
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Clearmind Medicine Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Clearmind Medicine Inc Stock Events

Financials Calendars

Event	Date	Price (€)
General meeting for 2026	2026-12-29 09:00	In 166 days
Third quarter earnings results for 2026	2026-09-11	In 56 days
Second quarter earnings results for 2026	2026-06-15	22.56 (+0.00%)
0.1:1 Stock Split	2026-05-21	22.56 (+0.00%)
First quarter earnings results for 2026	2026-03-12	22.56 (+0.00%)
Annual report for 2025	2026-01-20	22.56 (+0.00%)
General meeting for 2025	2025-12-29 09:00	22.56 (+0.00%)
0.025:1 Stock Split	2025-12-15	25.48 (-1.09%)
Third quarter earnings results for 2025	2025-09-11	339.80 (+0.24%)
Second quarter earnings results for 2025	2025-06-12	309.40 (+2.52%)

Show

Entries

Clearmind Medicine Inc Frequently Asked Questions

What is Clearmind Medicine Inc(FRA:CWY0)'s stock price today?

The current price of FRA:CWY0 is €22.56. The 52 week high of FRA:CWY0 is €391.00 and 52 week low is €22.55.

When is next earnings date of Clearmind Medicine Inc(FRA:CWY0)?

The next earnings date of Clearmind Medicine Inc(FRA:CWY0) is 2026-09-11 Est..

Does Clearmind Medicine Inc(FRA:CWY0) pay dividends? If so, how much?

Clearmind Medicine Inc(FRA:CWY0) does not pay dividend.

Press Release

	Subject	Date
	Moonage Media Review: Clearmind's MEAI and GLP-1 - Are These the Next-Generation Treatment for Weight Loss?	2026-02-19
	Aegis Capital Corp. Acted as Sole Bookrunner on a $2.4 Million Registered Direct and Private Placement for Clearmind Medicine Inc. (NASDAQ: CMND)	2024-01-16
	Thinking about buying stock in Yoshiharu Global Co, FREYR Battery, Cameco Corp, Arbor Realty Trust, or Clearmind Medicine?	2023-11-29
	Aegis Capital Corp. Acted as Exclusive Placement Agent on a $2.25 Million Public Offering for Clearmind Medicine Inc. (NASDAQ:CMND)	2023-09-19
	Israel-Based Clearmind Medicine Inc. CEO Discusses the Potential of Psychedelics for Addiction Treatment in Audio Interview with SmallCapVoice.com	2023-01-04

10/Page

Articles on Clearmind Medicine Inc

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.